| Stage | CNMD | % of rev | MDT | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $336M | 100.00% | $9.8B | 100.00% | MDT ×29.07 |
| Gross profit | $189M | 56.37% | $6.3B | 64.99% | MDT +8.6pp |
| Operating income | $37M | 11.07% | $1.8B | 18.08% | MDT +7.0pp |
| Pre-tax income | $26M | 7.75% | $1.8B | 18.13% | MDT +10.4pp |
| Net income | $20M | 5.90% | $1.5B | 15.16% | MDT +9.3pp |
| Stage | CNMD | MDT | Gap · A − B |
|---|---|---|---|
| Revenue | $336M100.00% | $9.8B100.00% | MDT ×29.07 |
| Gross profit | 56.37%$189M | 64.99%$6.3B | MDT +8.6pp |
| Operating income | 11.07%$37M | 18.08%$1.8B | MDT +7.0pp |
| Pre-tax income | 7.75%$26M | 18.13%$1.8B | MDT +10.4pp |
| Net income | 5.90%$20M | 15.16%$1.5B | MDT +9.3pp |
No shared counterparties.